MX2016010030A - Proteina quimerica compuesta del dominio antagonista de factor de crecimiento nervioso secretado (ngf) y un dominio antagonista de factor alfa de necrosis tumoral (tnfa). - Google Patents
Proteina quimerica compuesta del dominio antagonista de factor de crecimiento nervioso secretado (ngf) y un dominio antagonista de factor alfa de necrosis tumoral (tnfa).Info
- Publication number
- MX2016010030A MX2016010030A MX2016010030A MX2016010030A MX2016010030A MX 2016010030 A MX2016010030 A MX 2016010030A MX 2016010030 A MX2016010030 A MX 2016010030A MX 2016010030 A MX2016010030 A MX 2016010030A MX 2016010030 A MX2016010030 A MX 2016010030A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonist
- domain
- factor
- tnfa
- ngf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La descripción proporciona las composiciones y los métodos para controlar el dolor. En particular la descripción proporciona un método para controlar el dolor, que comprende la co-administración de un antagonista de NGF y un antagonista de TNFa. El antagonista de NGF y el antagonista de TNFa pueden ser moléculas separadas o parte de un polipéptido multifuncional, por ejemplo, una molécula de enlace multiespecífica que comprende un dominio antagonista de NGF y un dominio antagonista de TNFa. Esta descripción también proporciona los polipéptidos multifuncionales, por ejemplo, las moléculas de enlace multiespecíficas, que comprenden un dominio antagonista de NGF, y un dominio antagonista de TNFa. El método proporciona el control mejorado del dolor. La administración de un antagonista de NGF y un antagonista de TNFa como se proporciona en la presente, puede controlar el dolor en el sujeto más efectivamente que una cantidad equivalente del antagonista de NGF o el antagonista de TNFa administrados solos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934828P | 2014-02-02 | 2014-02-02 | |
| PCT/EP2015/052098 WO2015114150A1 (en) | 2014-02-02 | 2015-02-02 | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016010030A true MX2016010030A (es) | 2017-04-27 |
| MX382763B MX382763B (es) | 2025-03-13 |
Family
ID=52440681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010030A MX382763B (es) | 2014-02-02 | 2015-02-02 | Proteina quimerica compuesta del dominio antagonista de factor de crecimiento nervioso secretado (ngf) y un dominio antagonista de factor alfa de necrosis tumoral (tnfa). |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US9884911B2 (es) |
| EP (2) | EP3099713B1 (es) |
| JP (4) | JP6687526B2 (es) |
| KR (1) | KR102489452B1 (es) |
| CN (2) | CN118085103A (es) |
| AU (3) | AU2015212787B2 (es) |
| CA (1) | CA2938066C (es) |
| CY (1) | CY1123248T1 (es) |
| DK (1) | DK3099713T3 (es) |
| ES (1) | ES2784238T3 (es) |
| HR (1) | HRP20200477T1 (es) |
| HU (1) | HUE048478T2 (es) |
| LT (1) | LT3099713T (es) |
| MX (1) | MX382763B (es) |
| PL (1) | PL3099713T3 (es) |
| PT (1) | PT3099713T (es) |
| RS (1) | RS60156B1 (es) |
| RU (1) | RU2678810C2 (es) |
| SI (1) | SI3099713T1 (es) |
| SM (1) | SMT202000182T1 (es) |
| WO (1) | WO2015114150A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3099713T3 (da) * | 2014-02-02 | 2020-04-14 | Medimmune Ltd | Kimært protein bestående af et ngf-antagonistdomæne og et tnfa-antagonistdomæne |
| US9862760B2 (en) | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
| RU2020113713A (ru) | 2017-09-21 | 2021-10-21 | Мерк Патент Гмбх | Слитый белок, содержащий молекулу fgf-18 |
| WO2021142573A1 (zh) * | 2020-01-13 | 2021-07-22 | 丁邦 | 一种融合蛋白及其制法和用途 |
| EP4217388A1 (en) * | 2020-09-28 | 2023-08-02 | MedImmune Limited | Compounds and methods for treating pain |
| CN114574444B (zh) * | 2020-12-01 | 2024-05-03 | 达达生物技术(北京)有限公司 | 自体纤维母细胞在制备抗类风湿关节炎药物中的应用 |
| TWI821881B (zh) * | 2021-01-29 | 2023-11-11 | 醫研生物科技有限公司 | 腫瘤壞死因子α重組抗體及其用途 |
| CN116179667A (zh) * | 2022-09-21 | 2023-05-30 | 福建中妆技术研究有限公司 | 基于斑马鱼模型中trpv1信号通路筛选皮肤疼痛舒缓原料的试剂盒及应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2315944A1 (en) * | 1997-12-24 | 1999-07-08 | Diatech Pty. Ltd. | Bifunctional molecules |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| DE19926068C1 (de) * | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| CA2975521A1 (en) | 2001-05-30 | 2002-12-05 | Genentech, Inc. | Anti-ngf antibodies for the treatment of various disorders |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| US7252822B2 (en) | 2002-10-08 | 2007-08-07 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist |
| US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| EP1685161A1 (en) | 2004-08-30 | 2006-08-02 | Lonza Biologics plc | Affinity- plus ion exchange-chromatography for purifying antibodies |
| EP1846451B1 (en) * | 2005-01-24 | 2013-05-15 | Medimmune Limited | Human antibodies against human ngf |
| EP2418223A3 (en) * | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| KR20100021601A (ko) * | 2007-05-14 | 2010-02-25 | 바이오겐 아이덱 엠에이 인코포레이티드 | 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법 |
| WO2009092014A1 (en) | 2008-01-18 | 2009-07-23 | Gagnon Peter S | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
| JP2011523853A (ja) | 2008-06-03 | 2011-08-25 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリン及びその使用 |
| BRPI0915448A2 (pt) * | 2008-07-08 | 2015-11-10 | Abbott Lab | imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas |
| JP2011016676A (ja) * | 2009-07-07 | 2011-01-27 | Sumitomo Electric Ind Ltd | 窒化物半導体基板の製造方法 |
| TW201119676A (en) * | 2009-10-15 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US8722615B2 (en) | 2009-12-02 | 2014-05-13 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life |
| CN102958537B (zh) * | 2010-04-07 | 2015-09-16 | Abbvie公司 | TNF-α结合蛋白 |
| EP2714738B1 (en) * | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| EP2776061B1 (en) | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
| AR090047A1 (es) | 2011-12-30 | 2014-10-15 | Abbvie Inc | Dominio variable dual de inmunoglobulinas y sus usos |
| EP2938634A2 (en) * | 2012-12-28 | 2015-11-04 | AbbVie Inc. | Dual specific binding proteins having a receptor sequence |
| WO2014144299A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα |
| DK3099713T3 (da) | 2014-02-02 | 2020-04-14 | Medimmune Ltd | Kimært protein bestående af et ngf-antagonistdomæne og et tnfa-antagonistdomæne |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| US20210009671A1 (en) | 2019-05-10 | 2021-01-14 | Medimmune Limited | Compounds and methods for treating pain |
-
2015
- 2015-02-02 DK DK15701985.2T patent/DK3099713T3/da active
- 2015-02-02 EP EP15701985.2A patent/EP3099713B1/en active Active
- 2015-02-02 MX MX2016010030A patent/MX382763B/es unknown
- 2015-02-02 HR HRP20200477TT patent/HRP20200477T1/hr unknown
- 2015-02-02 SM SM20200182T patent/SMT202000182T1/it unknown
- 2015-02-02 WO PCT/EP2015/052098 patent/WO2015114150A1/en not_active Ceased
- 2015-02-02 SI SI201531149T patent/SI3099713T1/sl unknown
- 2015-02-02 PL PL15701985T patent/PL3099713T3/pl unknown
- 2015-02-02 CN CN202311359790.8A patent/CN118085103A/zh active Pending
- 2015-02-02 CA CA2938066A patent/CA2938066C/en active Active
- 2015-02-02 CN CN201580017113.5A patent/CN106459190A/zh active Pending
- 2015-02-02 HU HUE15701985A patent/HUE048478T2/hu unknown
- 2015-02-02 LT LTEP15701985.2T patent/LT3099713T/lt unknown
- 2015-02-02 EP EP19214210.7A patent/EP3696193A1/en active Pending
- 2015-02-02 KR KR1020167023831A patent/KR102489452B1/ko active Active
- 2015-02-02 AU AU2015212787A patent/AU2015212787B2/en active Active
- 2015-02-02 JP JP2016549449A patent/JP6687526B2/ja active Active
- 2015-02-02 PT PT157019852T patent/PT3099713T/pt unknown
- 2015-02-02 RU RU2016132370A patent/RU2678810C2/ru active
- 2015-02-02 US US14/612,137 patent/US9884911B2/en active Active
- 2015-02-02 ES ES15701985T patent/ES2784238T3/es active Active
- 2015-02-02 RS RS20200396A patent/RS60156B1/sr unknown
-
2017
- 2017-12-21 US US15/849,771 patent/US10457728B2/en active Active
-
2019
- 2019-09-17 US US16/573,192 patent/US11053307B2/en active Active
-
2020
- 2020-04-01 JP JP2020065513A patent/JP7074792B2/ja active Active
- 2020-04-10 CY CY20201100338T patent/CY1123248T1/el unknown
- 2020-09-11 AU AU2020230316A patent/AU2020230316B2/en active Active
-
2021
- 2021-05-28 US US17/333,291 patent/US11897949B2/en active Active
-
2022
- 2022-05-11 JP JP2022077858A patent/JP7520070B2/ja active Active
-
2023
- 2023-12-21 AU AU2023285832A patent/AU2023285832A1/en active Pending
-
2024
- 2024-01-03 US US18/403,043 patent/US20240262902A1/en not_active Abandoned
- 2024-07-08 JP JP2024109298A patent/JP2024133644A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016010030A (es) | Proteina quimerica compuesta del dominio antagonista de factor de crecimiento nervioso secretado (ngf) y un dominio antagonista de factor alfa de necrosis tumoral (tnfa). | |
| CL2020002043A1 (es) | Métodos y composiciones para la entrega de proteínas terapeuticas. | |
| CO2019002609A2 (es) | Proteínas de unión recombinantes y sus usos | |
| CY1124896T1 (el) | Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων | |
| CO2017008047A2 (es) | Polipéptidos que se unen a proteínas de la superfamilia del receptor del factor de necrosis tumoral | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| ECSP17063327A (es) | Receptores de antígeno quiméricos antidll3 y métodos de uso | |
| EP3515420C0 (en) | PHARMACEUTICAL COMPOSITIONS FOR USE IN BLEPHARITIS THERAPY | |
| BR112017008157A2 (pt) | polipeptídeos de fgf-21 modificados e usos dos mesmos | |
| MX2015011445A (es) | Compuestos y usos de estos para la modulacion de la hemoglobina. | |
| AR100215A1 (es) | Conjugados de anticuerpo-fármaco anti-ptk7 | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| GT201400057A (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
| CL2014001547A1 (es) | Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales. | |
| MX369653B (es) | Formulaciones de anticuerpos y proteinas. | |
| UY35407A (es) | ?PROTEÍNAS DE FUSIÓN COMPRENDIENDO PORCIONES PDGF y VEGF DE UNIÓN Y MÉTODOS PARA SU USO?. | |
| EA202090632A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| MX376324B (es) | Proteinas de union a desmogelina 2 (dsg2) y usos de los mismos. | |
| MX359201B (es) | Polipeptidos que se unen al complemento humano 5 (c5). | |
| EA202191513A1 (ru) | Снижение вязкости фармацевтических составов | |
| EP3915583A4 (en) | COMBINED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS | |
| BR112016025866A2 (pt) | composição farmacêutica, método para tratar uma doença anti-inflamatória em um indivíduo, método para tratar uma doença autoimune em um indivíduo, método para tratar um câncer em um indivíduo, uso de uma molécula de fusão que não ocorre naturalmente, método para tratar um distúrbio metabólico em um indivíduo, método para tratar uma doença hepática gordurosa em um indivíduo, método para tratar um distúrbio de deficiência de hormônio de crescimentoem um indivíduo, e, polinucleotídeo que codifica uma molécula de fusão | |
| MX2017000698A (es) | Uso terapeutico de la proteina de union a neurotrofina p75ntr. | |
| EA201790615A1 (ru) | Композиции и способы увеличения захвата железа у млекопитающих | |
| EA201591421A1 (ru) | Препараты полипептида фактора ix |